ABSTRACT NUMBER - 121

THE NSW EXPERIENCE WITH OZURDEX IN NON-INFECTIOUS UVEITIS


Matthew McCartney1, Sophia Zagora2, Peter McCluskey3

Meeting:  2018 RANZCO


SESSION INFORMATION

Date:      -

Session Title: POSTER ABSTRACT- UVEITIS

Session Time:      -

Introduction: With continuing advancements in the treatment of non-infectious Uveitis through intravi- treal steroids, large centres worldwide are assessing the benefits of these therapies, in comparison to established therapies, in view of efficacy, safety and medication load reduction. Our review highlights the experience of a single Australian centre from 2012 to present with Ozurdex, an intravitreal dexa- methasone implant.
Method: Retrospective review of 62 implants placed in 17 eyes of 14 patients with non-infectious uveitis between 2012 and April 2018. All patients commenced on therapy were previously unsuccess- ful with local and/or systemic therapy. The struc- tured post-injection review assessed best-corrected visual acuity (BCVA), optical coherence tomography (OCT) derived central retinal thickness (CRT), adjunct medication reduction and patient satisfaction.
Results: In our cohort, intravitreal dexamethasone demonstrated clinically significant stabilisation or improvement in BCVA, improved CRT in 85% of eyes. In addition, a majority of patients either were able to reduce or cease systemic steroid therapy.
Conclusion: While larger studies are required, this review presents Ozurdex as a potentially highly effective treatment option for non-infectious Uveitis, in particular, those cases with cystoid macular oedema.

MOST VIEWED ABSTRACTS


ARCHIVES